Compare Amazon.com Inc (AMZN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Incyte Corporation — how do they compare? Amazon.com Inc trades at $267.6 (market cap $2.94T), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Amazon.com Inc is far larger — about 119.8× Incyte Corporation's market cap. Which is the better fit depends on your goals.
| AMZN | INCY | |
|---|---|---|
Market Cap | $2.94T | $24.54B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $129.93 |
52-Week Low | $198.79 | $81.61 |
Enterprise Value | $3.04T | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $272.27, down 2.09% today but maintains strong fundamentals with robust revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Technical indicators show a bullish trend with support at $271 and resistance at $275, while analyst consensus remains overwhelmingly positive with 89% buy ratings and a $333.86 price target. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS growth and AI chip business expansion.
Amazon presents a compelling investment case with accelerating profitability and dominant market positioning, though investors face risks from intense competition and significant capital expenditures. The stock's current valuation at 21.9x P/E appears reasonable given projected 2026 net income growth to $135.3B, supporting potential upside to analyst targets despite near-term market volatility.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
